Why Did Redcare Pharmacy (XTRA:RDC) Move Today?

Redcare Pharmacy (XTRA:RDC) is back in focus after the company announced that CEO Olaf Heinrich will step down after three years, including his role on the Managing Board. He will, however, remain available in an advisory capacity.

The CEO transition comes at a time when Redcare Pharmacy’s share price has been volatile, with a 1 day share price return of 4.29% but a 7 day share price return down 6.22%. The 90 day share price return of 23.24% contrasts with a 1 year total shareholder return that has declined 17.86%, which indicates that recent positive momentum is still set against weaker longer term outcomes as investors reassess leadership and execution risk.

Spot similar leadership driven setups by scanning our hand picked 617 high quality undiscovered gems, which may be flying under the radar despite recent share price swings.

For Redcare Pharmacy, that sharp recent rebound against a weaker 1 year and multi year record puts you at a fork in the road. Lean into the volatility now, or wait and hope for a cheaper entry once the CEO change settles?

Preferred Price-to-Sales Multiple of 0.4x: Is It Justified?

At a last close of €59.55, Redcare Pharmacy is flagged as expensive on a preferred price-to-sales (P/S) multiple of 0.4x, especially when set against both its peers and an estimated fair level.

The P/S ratio compares the value that the market places on the company to the revenue it generates. For an online pharmacy like Redcare Pharmacy, which is currently loss making with annual revenue of €3,217.4m and a reported net loss of €42.0m, investors are effectively using sales as a primary reference point rather than earnings.

On that measure, Redcare Pharmacy trades on a P/S of 0.4x. This is described as expensive compared to the European Consumer Retailing industry average of 0.4x and also expensive relative to the peer average of 0.3x. The stock is also described as expensive versus an estimated fair P/S ratio of 0.2x, which suggests material room for the market multiple to compress towards that fair ratio if sentiment or growth expectations cool.

Result: Price-to-Sales of 0.4x (OVERVALUED)

Explore the SWS fair ratio for Redcare Pharmacy

However, Redcare Pharmacy is still loss making, and the CEO change introduces fresh execution risk that could unsettle sentiment if revenue growth or margins disappoint.

Find out about the key risks to this Redcare Pharmacy narrative.

Another View On Redcare Pharmacy’s Value

The P/S screen presents Redcare Pharmacy as expensive, yet our DCF model suggests a different perspective. At €59.55 the stock is described as trading about 82.6% below an estimated future cash flow value of €341.61. That indicates a very different risk and reward balance for you to weigh.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Redcare Pharmacy for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 257 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment on Redcare Pharmacy clearly mixed, it may be helpful to review the underlying data and form your own stance. To weigh both sides of the story, start by checking the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Redcare Pharmacy?

If you stop with Redcare Pharmacy, you could miss other compelling setups. Use the screeners below to quickly surface stocks that better fit your risk and return goals.

• Target resilient companies with downside protection by using our 308 resilient stocks with low risk scores that filters for stocks with stronger risk profiles.
• Spot potential value opportunities before the crowd by checking the 257 high quality undervalued stocks built around quality fundamentals and attractive pricing.
• Strengthen your income focus by reviewing the 417 dividend fortresses that highlights companies offering higher dividend yields.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com